JP2024519845A5 - - Google Patents

Info

Publication number
JP2024519845A5
JP2024519845A5 JP2023571509A JP2023571509A JP2024519845A5 JP 2024519845 A5 JP2024519845 A5 JP 2024519845A5 JP 2023571509 A JP2023571509 A JP 2023571509A JP 2023571509 A JP2023571509 A JP 2023571509A JP 2024519845 A5 JP2024519845 A5 JP 2024519845A5
Authority
JP
Japan
Prior art keywords
inhibitors
pharmaceutically acceptable
yap
taz
tead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072452 external-priority patent/WO2022246459A1/en
Publication of JP2024519845A publication Critical patent/JP2024519845A/ja
Publication of JP2024519845A5 publication Critical patent/JP2024519845A5/ja
Pending legal-status Critical Current

Links

JP2023571509A 2021-05-19 2022-05-19 併用療法 Pending JP2024519845A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190766P 2021-05-19 2021-05-19
US63/190,766 2021-05-19
PCT/US2022/072452 WO2022246459A1 (en) 2021-05-19 2022-05-19 Combination therapy

Publications (2)

Publication Number Publication Date
JP2024519845A JP2024519845A (ja) 2024-05-21
JP2024519845A5 true JP2024519845A5 (https=) 2025-05-27

Family

ID=82492721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571509A Pending JP2024519845A (ja) 2021-05-19 2022-05-19 併用療法

Country Status (7)

Country Link
US (1) US20240148733A1 (https=)
EP (1) EP4340883A1 (https=)
JP (1) JP2024519845A (https=)
CN (1) CN117337193A (https=)
AR (1) AR125921A1 (https=)
TW (1) TW202313048A (https=)
WO (1) WO2022246459A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240055778A (ko) * 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2024176131A1 (en) * 2023-02-23 2024-08-29 Novartis Ag Tead- and kras g12d-inhibitor combinations for treating cancer
AU2024242687A1 (en) * 2023-03-27 2025-10-09 Vivace Therapeutics, Inc. Synthesis of a hippo-yap pathway modulator and a polymorph thereof
WO2025054190A1 (en) * 2023-09-05 2025-03-13 Vivace Therapeutics, Inc. Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor
WO2025101655A1 (en) * 2023-11-08 2025-05-15 Vivace Therapeutics, Inc. Compounds for modulating yap-tead/hippo pathway
WO2025122956A1 (en) * 2023-12-08 2025-06-12 Vivace Therapeutics, Inc. Combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018273356B2 (en) * 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11192865B2 (en) * 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
LT3710439T (lt) * 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
KR20210108367A (ko) * 2018-11-09 2021-09-02 비바체 테라퓨틱스, 인크. 비시클릭 화합물
PE20260440A1 (es) * 2018-11-09 2026-02-19 Hoffmann La Roche Compuestos de anillo fusionado
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021012638A (es) * 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
TW202130618A (zh) * 2019-11-13 2021-08-16 美商建南德克公司 治療性化合物及使用方法
JP7759877B2 (ja) * 2019-11-27 2025-10-24 ジェネンテック， インコーポレイテッド 治療用化合物
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN115210227A (zh) * 2020-03-04 2022-10-18 基因泰克公司 作为tead抑制剂的异双功能分子
WO2021224291A1 (en) * 2020-05-08 2021-11-11 Merck Patent Gmbh Tricyclic heterocycles useful as tead binders
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use

Similar Documents

Publication Publication Date Title
JP2024519845A5 (https=)
JP7492002B2 (ja) Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法
WO2006080327A1 (ja) α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
NO338380B1 (no) Anvendelse av et terapeutisk preparat av et PBD-derivat, samt et produkt derav
EA037152B1 (ru) Способ лечения рака
AU2007264665B2 (en) Potentiator of radiation therapy
JP3208437B2 (ja) 癌転移抑制剤
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
EP4486345A1 (en) Method of treatment including kras g12c inhibitors and shp2 inhibitors
JP6549107B2 (ja) がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
JP2005527552A (ja) 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療
KR20240159340A (ko) 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법
JP6239745B2 (ja) がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
JP5581200B2 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
US20090239872A1 (en) Treatment of mesothelioma
HK40078096A (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
AU2003299065A1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
HK1118704B (en) Radiotherapy enhancer
HK1118704A1 (en) Radiotherapy enhancer
HK1148204B (en) Radiotherapy enhancer
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤